Cybin Inc. and Small Pharma Join Forces in a Milestone Psychedelic Therapeutics Acquisition

LOS ANGELES- In a notable merger move in the psychedelic therapeutics landscape, Small Pharma Inc. has received the green light from the Supreme Court of British Columbia for its acquisition by Cybin Inc. This all-stock transaction, slated for completion around Oct. 23, will lead to Small Pharma’s shares being delisted from the Toronto Stock Exchange.

Deal Insights:

The August announcement of Cybin’s intent to acquire Small Pharma aims to blend the strengths of both entities, positioning them at the forefront of developing psychedelic-based solutions for mental health challenges. As reported by Green Market Report, the unification of their concerted efforts will amalgamate a portfolio boasting 28 granted patents and an impressive 158 pending patents. This strategic move is anticipated to foster “strong synergies”, merging pivotal assets, elite personnel, and profound capabilities.

Prominent Clinical Milestones Ahead:

The collaborative prowess will manifest in an expansive clinical program encompassing:

1. Safety & Efficacy Trials: Intensive scrutiny into the safety and potential of intravenous (IV) DMT as a therapeutic solution for major depression.
2. Data-Driven Decisions: Accumulation of substantial data from the preliminary trials of IV DMT and its deuterated counterpart, dDMT.
3. Enhanced Patient Experience: Investigative pursuits into more patient-friendly and convenient methods of administering these drugs.

Come the close of 2023, the industry and stakeholders eagerly await results from the inaugural trials of dDMT. This data will significantly influence the decision to spearhead an advanced Phase 2 trial in the U.S. by 2024’s onset, focusing on the potential of dDMT in treating specific mental health conditions.

Additionally, the acquisition will expedite the development trajectory of Cybin’s synthetic psilocybin, CYB003, propelling it to Phase 3 by early 2024. This follows the anticipated Phase 2 outcomes on its safety and efficacy slated for release in late 2023.

Cybin’s CYB003 has already shown promise, as revealed earlier this month. In its ongoing patient testing for doses up to 12 milligrams, CYB003 has exhibited a “favorable safety and tolerability profile”, with no reports of severe adverse events.

A Visionary Future:

Mergers like this signal a transformative era for psychedelic therapeutics. With heavyweights like Cybin Inc. and Small Pharma converging, the industry stands on the cusp of revolutionary discoveries and therapies. As the race towards establishing evidence-based psychedelic treatments for mental health accelerates, collaborations of this magnitude will undeniably pave the path forward.